The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: Considerations for optimal use

Clinical Therapeutics

Volumn 27, Issue 3, 2005, Pages 273-285

  Teillac, Pierre ^a   Bono, Aldo V ^b   Irani, Jacques ^c   Wirth, Manfred P ^d   Zlotta, Alexandre R ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b OSPEDALE DI CIRCOLO   (Italy)

^c UNIVERSITÉ DE POITIERS   (France)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e ERASME HOSPITAL   (Belgium)

Author keywords

Biochemical failure; Hormone therapy; LHRH analogues; Prostate cancer; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN; GONADORELIN DERIVATIVE; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUPRORELIN; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SILDENAFIL; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANEMIA; BIOCHEMISTRY; BODY COMPOSITION; BODY FAT; BONE; BONE DENSITY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FATIGUE; GYNECOMASTIA; HAIR LOSS; HOT FLUSH; HUMAN; LIBIDO DISORDER; LONG TERM CARE; MEDICAL LITERATURE; MEDLINE; MENTAL DISEASE; MUSCLE ATROPHY; MUSCLE MASS; OSTEOPENIA; OSTEOPOROSIS; PHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; PUBLICATION; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

EID: 18844402210     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.02.016     Document Type: Article

References (51)

1. for the American Society of Clinical Oncology Loblaw D.A., Mendelson D.S., and Talcott J.A. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitivity metastatic, recurrent, orprogressive prostate cancer [published correction appears in J Clin Oncol. 2004;22:4435] J Clin Oncol. 22 2004 2927 2941
2. American Cancer Society. Cancer facts & figures 2004. Available at: http://www.cancer.org. Accessed January 5, 2005.
3. Khan M.A., and Partin A.W. Management of high-risk populations with locally advanced prostate cancer Oncologist 8 2003 259 269
4. Crawford E.D. The role of hormonal therapy in the treatment of locally advanced prostate cancer-regional perspectives: USA Eur Ural Suppl. 3 2004 17 21
5. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer N Engl J Med. 349 2003 366 381
6. Bolla M., Collette L., and Blank L. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
7. Abstract 1284 Hanks G.E., Lu J.D., and Machtay M. RTOG protocol 9202: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction andradiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys. 48 Suppl 1 2000 112
8. Messing E.M., Manola J., and Sarosdy M. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med. 341 1999 1781 1788
9. Seay T.M., Blute M.L., and Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation J Urol. 159 1998 357 364
10. Abstract Prayer-Galetti T., Zattoni F., and Capizzi A. Disease free survival in patients with pathological "C STAGE" prostate cancer at radical retropubic prostatectomy submitted to adjuvanthormonal treatment Eur Urol. 38 2000 504
11. Pilepich M.V., Caplan R., and Byhardt R.W. Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy:Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol. 15 1997 1013 1021
12. Lawton C.A., Winter K., and Murray K. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppressionfollowing standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys. 49 2001 937 946
13. Pisansky T.M. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostatecancer Urology 62 Suppl 1 2003 36 45
14. Wirth M.P., and Froehner M. Value of endocrine therapy for early and locally advanced prostate cancer Drugs Aging 20 2003 115 124
15. Cheng L., Zincke H., and Blute M.L. Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 2001 66 73
16. Pilepich M.V., Winter K., and John M.J. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advancedcarcinoma of the prostate Int J Radiat Oncol Biol Phys. 50 2001 1243 1252
17. Aus G., Abrahamsson P.A., and Ahlgren G. Hormonal treatment before radical prostatectomy: A 3-year followup J Urol. 159 1998 2013 2017
18. Schulman C.C., Debruyne F.M., Forster G. European Study Group on Neoadjuvant Treatment of Prostate Cancer 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer Eur Urol. 38 2000 706 713
19. Gleave M.E., Goldenberg S.L., Chin J.L. Canadian Uro-Oncology Group Randomized com parative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects J Urol. 166 2001 500 507
20. Pound C.R., Partin A.W., and Eisenberger M.A. Natural history of progression after PSA elevation follow ing radical prostatectomy JAMA 281 1999 1591 1597
21. Pollack A., Hanlon A.L., and Movsas B. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy Int J Radiat Oncol Biol Phys. 57 2003 19 23
22. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement: Guide lines for PSA following radiation therapy Int J Radiat Oncol Biol Phys. 37 1997 1035 1041
23. D'Amico A.V., Whittington R., and Malkowicz S.B. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
24. Crook J., Malone S., and Perry G. Postradiotherapy prostate biopsies: What do they really mean? Results from 498 patients Int J Radiat Oncol Biol Phys. 48 2000 355 367
25. Kestin L.L., Vicini F.A., and Ziaja E.L. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1999 1557 1566
26. Zietman A.L., Tibbs M.K., and Dallow K.C. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate Radiother Oncol. 40 1996 159 162
27. Lee W.R., Hanlon A.L., and Hanks G.E. Prostate specific antigen nadir following external beam radiation ther apy for clinically localized prostate cancer: The relationship between nadirlevel and disease-free survival J Urol. 156 1996 450 453
28. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy 0 N Engl J Med. 351 2004 125 135
29. Kupelian P.A., Elshaikh M., and Reddy C.A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy J Clin Oncol. 20 2002 3376 3385
30. Moul J.W. Variables in predicting survival based on treating "PSA-only" relapse Urol Oncol. 21 2003 292 304
31. Cannon G.M. Jr, Walsh P.C., Partin A.W., and Pound C.R. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer Urology 62 Suppl 6B 2003 2 8
32. Pilepich M.V., Winter K., and Lawton C. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of phase III RTOG study 85-31 Int J Radiat Oncol Biol Phys. 57 Suppl 1 2003 5172 5173
33. The Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial 0 Br J Urol. 79 1997 235 246
34. Abstract 1574 Reynolds W., Wu J., and Sun L. Comparison of early versus late hormonal therapy (HT) following early PSA-only recurrence (ePSAR) within the Department of Defense Center forProstate Disease Research Database Proc Am Soc Clin Oncol. 22 2003 392
35. Moul J.W., Wu H., and Sun L. Early versus delayed hormonal therapy for prostate specific antigen only recur rence of prostate cancer after radical prostatectomy J Urol. 171 2004 1141 1147
36. Available at Verbaeys A., Moonen L., Studer U., and Pansadoro V. European Organisation for Research and Treatment of Cancer (EORTC) Accessed Protocol 30943 March 4, 2004
37. Available at Hussain M.H.A., Higano C.S., and Miles B.J. Phase III randomized study of intermittent versus continuous com bined androgen-deprivation therapy comprising bicalutamide and goserelin in patients with metastatic stage IV prostate cancer responsive to such therapy Accessed Protocol SWOG9346 March 4, 2004
38. Higano C.S. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity Urology 61 Suppl 1 2003 32 38
39. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function dur ing the first cycle of intermittent androgen suppression in patients withprostate cancer J Urol. 170 2003 1808 1811
40. Salminen E., Portin R., and Korpela J. Androgen deprivation and cognition in prostate cancer Br J Cancer 89 2003 971 976
41. Taxel P., Stevens M.C., and Trahiotis M. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer J Am Geriatr Soc. 52 2004 269 273
42. Melton L.J. III, Alothman K.I., and Khosla S. Fracture risk following bilateral orchiectomy J Urol. 169 2003 1747 1750
43. Abstract 1207 Higano C., Stephens C., and Nelson P. Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittentandrogen suppression (IAS) Abstract presented at: American Society of Clinical Oncology 35th Annual Meeting Atlanta, Ga. May 15-18, 1999
44. Smith M.R. Management of treatment-related osteoporosis in men with prostate cancer Cancer Treat Rev. 29 2003 211 218
45. Smith M.R., Finkelstein J.S., and McGovern F.J. Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab. 87 2002 599 603
46. for the Saad F., Gleason D.M., Murray R. Zoledronic Acid Prostate Cancer Study Group A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma J Natl Cancer Inst. 94 2002 1458 1468
47. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer CA Cancer J Clin. 52 2002 154 179
48. Albrecht W., Collette L., and Fava C. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study Eur Urol. 44 2003 505 511
49. De La Taille A., Zerbib M., and Conquy S. Intermittent androgen suppression in patients with prostate cancer BJU Int. 91 2003 18 22
50. Gingrich J.R., Barrios R.J., and Morton R.A. Metastatic prostate cancer in a transgenic mouse Cancer Res. 56 1996 4096 4102
51. Bruchovsky N., Klotz L.H., and Sadar M. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations Mol Urol. 4 2000 191 199